Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081926 · ClinicalTrials.gov registry record · Phase 4
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
NCT00081926 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 112 participants.
The verdict
NCT00081926, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
Study Summary
This study will evaluate the molecular response to high dose Gleevec in newly diagnosed patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase. This study will evaluate the ability of Gleevec to reduce the amount of abnormal protein that occurs in patients with CML. Patients who are eligible to participate will be treated for 18 months. This trial will include male or female patients 18 years or older who are newly diagnosed (within 6 months) with CML.
Interventions
- DRUG Gleevec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081926
The ClinicalTrials.gov registry entry for NCT00081926 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gleevec is the first listed.
NCT00081926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081926 about?
NCT00081926 is a clinical study titled "Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". This study will evaluate the molecular response to high dose Gleevec in newly diagnosed patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase. This study will evaluate the ability of Gleevec to reduce the amount of abnormal protein that occurs in patients with CML. Patients who are elig...
What is the current status of trial NCT00081926?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2003-10. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00081926?
The interventions under investigation include: Gleevec (DRUG).
Who is sponsoring clinical trial NCT00081926?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.